logo/base Created with Sketch.

An innovative company dedicated to liver health

wave

Our vision & our mission

We are shaping the future of liver health.

 

We are empowering medical professionals to manage liver health for simpler, faster and better patient care.  

wave

More about echosens

317

employees over eight subsidiaries

82

distributors over the world

125

international patents granted

12%

of annual sales invested in product development

Discover Echosens and our commitment for liver health in video

play
quote

It’s about passionate and humble people that make us see simplicity out of complexity.
Before becoming a company, echosens was an idea. This idea has been growing from its root in Paris, within Prof. Fink’s lab. Initially, my PhD thesis paved the way for the development of transient elastography (TE), which we patented in 1999.

> 20 years of liver health – Continue the story

Laurent Sandrin | Founder and Chief Technology Officer at Echosens

In immersion at Echosens

play

Based on our values, Echosens is committed to achieving the Sustainable Development Goals

Echosens has been awarded the gold medal, ranking in the top 5% of over 100,000 companies assessed in 200 industries and 175 countries. The overall EcoVadis score obtained reflects the quality of the company’s ESG program.

c Courage
h Humility
o Openness
i Innovation
c Commitment
e Environment
s Simplicity

Inception in Paris

After Laurent Sandrin’s PhD thesis on transient elastography (TE), this technology found its application to quantify liver stiffness (LSM by VCTE) allowing a better patient care in hepatology…

First accomplishment: FibroScan® is born

The very first FibroScan® launched on the market is the FibroScan® 502. It was released during the EASL Congress in Geneva.

CAP™ parameter

In addition to VCTE, Echosens introduced a new, unique and patented technology calledCAP™ (Controlled Attenuation Parameter) for liver steatosis assessment, a true benefit to measure patient’s liver fat.

FibroScan® mobile generation

With FibroScan® Mini+ 430 and FibroScan® Compact 530, the FibroScan® family evolves to better fit physicians daily practice with mobility, user-friendliness and connectivity, ideal for multi-site configuration.

Scores: Fast

Fast is the optimal point-of-care comprehensive test for the identification of at risk MASH patients.

FibroScan® Expert 630

The complete non-invasive solution for advanced liver disease management, with the new Spleen Stiffness Measurement (SSM by VCTE™).

Scores: Agile 3+ and Agile 4

Agile 3+ for identification of advanced fibrosis in MASLD patients.
Agile 4 for identification of cirrhosis in MASLD patients.

FibroScan® GO

FibroScan® GO, an affordable, cost-effective solution with a pay-per-exam offer and all services included.

Guided VCTE™

Guided VCTE™, the Next-Generation FibroScan® technology for faster examinations with improved guidance.

Leadership team

Dominique Legros
Group Chief Executive Officer
Jon Gingrich
Chief Executive Officer North America
Lijuan Deng
Chief Executive Officer China
Laurent Sandrin
Founder and Chief Technology Officer